Cullinan presents initial Phase 1 CLN-978 data in SLE and RA at EULAR; 71% SLE response rate, 5 DORIS remissions

Cullinan Therapeutics, Inc.

In SLE (n=18), 10 of 14 patients (71%) with ≥4 weeks follow-up achieved ≥4-point hSLEDAI reduction; 5 attained DORIS remission.
In RA (n=11), disease activity improved in 5 of 7 evaluable patients (71%), including one DAS28-ESR remission at 30 µg target dose.
Peripheral B-cell depletion >80% in 82% of SLE patients; BLOQ depletion in 50% at target doses ≥20 µg. Dose-dependent depletion also seen in tissues.
CRS events in 11 of 29 patients (38%); mostly Grade 1. One Grade 3 CRS at 45 µg dose led to cohort discontinuation; no ICANS observed.
Company to host Immunology Day June 10 with additional CLN-978 multi-dose data and initial velinotamig data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.